Literature DB >> 30615514

Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.

Ramin Mojtabai1, Christine Mauro2, Melanie M Wall3, Colleen L Barry4, Mark Olfson5.   

Abstract

Medication treatment (MT) is one of the few evidence-based strategies proposed to combat the current opioid epidemic. We examined national trends and correlates of offering MT in substance use treatment facilities in the United States. According to data from national surveys, the proportion of these facilities that offered any MT increased from 20.0 percent in 2007 to 36.1 percent in 2016-mainly the result of increases in offering buprenorphine and extended-release naltrexone. Only 6.1 percent of facilities offered all three MT medications in 2016. Facilities in states with higher opioid overdose death rates, facilities that accepted health insurance overall (and, more specifically, those that accepted Medicaid in states that opted to expand eligibility for Medicaid), and facilities in states with more comprehensive coverage of MT under their Medicaid plans had higher odds of offering MT. The findings highlight the persistent unmet need for MT nationally and the role of expansion of health insurance in the dissemination of these treatments.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30615514      PMCID: PMC6816341          DOI: 10.1377/hlthaff.2018.05162

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  42 in total

1.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

2.  Both Urgency and Balance Needed in Addressing Opioid Epidemic: A Report From the National Academies of Sciences, Engineering, and Medicine.

Authors:  Richard J Bonnie; Aaron S Kesselheim; David J Clark
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

3.  Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications.

Authors:  Colleen M Grogan; Christina Andrews; Amanda Abraham; Keith Humphreys; Harold A Pollack; Bikki Tran Smith; Peter D Friedmann
Journal:  Health Aff (Millwood)       Date:  2016-12-01       Impact factor: 6.301

4.  Utilization and outcomes of detoxification and maintenance treatment for opioid dependence in publicly-funded facilities in California, USA: 1991-2012.

Authors:  Bohdan Nosyk; Libo Li; Elizabeth Evans; Darren Urada; David Huang; Evan Wood; Richard Rawson; Yih-Ing Hser
Journal:  Drug Alcohol Depend       Date:  2014-07-27       Impact factor: 4.492

5.  Reframing the Opioid Epidemic as a National Emergency.

Authors:  Lawrence O Gostin; James G Hodge; Sarah A Noe
Journal:  JAMA       Date:  2017-10-24       Impact factor: 56.272

6.  More Beds or More Chairs? Using a Science-Based Approach to Address the Opioid Epidemic.

Authors:  Jeanette M Tetrault; David A Fiellin
Journal:  Ann Intern Med       Date:  2017-11-21       Impact factor: 25.391

7.  Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: Historical perspective, lessons learned, and next steps.

Authors:  Jessica J Wyse; Adam J Gordon; Steven K Dobscha; Benjamin J Morasco; Elizabeth Tiffany; Karen Drexler; Friedhelm Sandbrink; Travis I Lovejoy
Journal:  Subst Abus       Date:  2018       Impact factor: 3.716

8.  Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment.

Authors:  Hefei Wen; Jason M Hockenberry; Tyrone F Borders; Benjamin G Druss
Journal:  Med Care       Date:  2017-04       Impact factor: 2.983

9.  Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.

Authors:  Lars Tanum; Kristin Klemmetsby Solli; Zill-E-Huma Latif; Jurate Šaltyte Benth; Arild Opheim; Kamni Sharma-Haase; Peter Krajci; Nikolaj Kunøe
Journal:  JAMA Psychiatry       Date:  2017-12-01       Impact factor: 21.596

10.  Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Authors:  Bobbi Jo H Yarborough; Scott P Stumbo; Dennis McCarty; Jennifer Mertens; Constance Weisner; Carla A Green
Journal:  Drug Alcohol Depend       Date:  2016-01-06       Impact factor: 4.492

View more
  49 in total

1.  Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016.

Authors:  Melanie S Askari; Silvia S Martins; Pia M Mauro
Journal:  J Subst Abuse Treat       Date:  2020-05-11

2.  Opioid Use Disorder Treatment Facilities With Programs for Special Populations.

Authors:  Scott E Hadland; Victoria A Jent; Rachel H Alinsky; Brandon D L Marshall; Pia M Mauro; Magdalena Cerdá
Journal:  Am J Prev Med       Date:  2020-05-21       Impact factor: 5.043

3.  The Affordable Care Act and Opioid Agonist Therapy for Opioid Use Disorder.

Authors:  Ramin Mojtabai; Christine Mauro; Melanie M Wall; Colleen L Barry; Mark Olfson
Journal:  Psychiatr Serv       Date:  2019-04-30       Impact factor: 3.084

4.  Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.

Authors:  Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn
Journal:  JAMA Netw Open       Date:  2020-02-05

5.  Missed Opportunities to Save Lives-Treatments for Opioid Use Disorder After Overdose.

Authors:  Elizabeth M Schoenfeld; Lauren M Westafer; William E Soares
Journal:  JAMA Netw Open       Date:  2020-05-01

6.  Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.

Authors:  Robert D Ashford; Austin M Brown; Jessica McDaniel; Jenna Neasbitt; Chad Sobora; Robert Riley; Lesley Weinstein; Aaron Laxton; Justin Kunzelman; Kyle Kampman; Brenda Curtis
Journal:  Addict Behav       Date:  2019-06-21       Impact factor: 3.913

7.  Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.

Authors:  Tae Woo Park; Marc R Larochelle; Richard Saitz; Na Wang; Dana Bernson; Alexander Y Walley
Journal:  Addiction       Date:  2020-01-20       Impact factor: 6.526

8.  U.S. alcohol treatment admissions after the Mental Health Parity and Addiction Equity Act: Do state parity laws and race/ethnicity make a difference?

Authors:  Nina Mulia; Camillia K Lui; Yu Ye; Meenakshi S Subbaraman; William C Kerr; Thomas K Greenfield
Journal:  J Subst Abuse Treat       Date:  2019-08-20

9.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

10.  Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.

Authors:  Noa Krawczyk; Ramin Mojtabai; Elizabeth A Stuart; Michael Fingerhood; Deborah Agus; B Casey Lyons; Jonathan P Weiner; Brendan Saloner
Journal:  Addiction       Date:  2020-02-24       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.